| Nasdaq: CYTR
CytRx Corp. is engaged in specializing oncology. It focuses on the clinical development of oncology pipelines for the treatment of cancer. It includes clinical-stage drug candidates in various stages of development such as Aldoxorubicin, Tamibarotene, and Bafenitib. The company was founded in 1985 and is headquartered in Los Angeles, CA.